1. Home
  2. ELVN vs BHE Comparison

ELVN vs BHE Comparison

Compare ELVN & BHE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ELVN
  • BHE
  • Stock Information
  • Founded
  • ELVN 2016
  • BHE 1979
  • Country
  • ELVN United States
  • BHE United States
  • Employees
  • ELVN N/A
  • BHE N/A
  • Industry
  • ELVN Biotechnology: Pharmaceutical Preparations
  • BHE Electrical Products
  • Sector
  • ELVN Health Care
  • BHE Technology
  • Exchange
  • ELVN Nasdaq
  • BHE Nasdaq
  • Market Cap
  • ELVN 1.2B
  • BHE 1.4B
  • IPO Year
  • ELVN 2020
  • BHE 1990
  • Fundamental
  • Price
  • ELVN $20.22
  • BHE $39.93
  • Analyst Decision
  • ELVN Strong Buy
  • BHE Strong Buy
  • Analyst Count
  • ELVN 5
  • BHE 2
  • Target Price
  • ELVN $41.20
  • BHE $46.50
  • AVG Volume (30 Days)
  • ELVN 335.0K
  • BHE 305.5K
  • Earning Date
  • ELVN 08-13-2025
  • BHE 07-30-2025
  • Dividend Yield
  • ELVN N/A
  • BHE 1.77%
  • EPS Growth
  • ELVN N/A
  • BHE N/A
  • EPS
  • ELVN N/A
  • BHE 1.05
  • Revenue
  • ELVN N/A
  • BHE $2,588,733,000.00
  • Revenue This Year
  • ELVN N/A
  • BHE $0.52
  • Revenue Next Year
  • ELVN N/A
  • BHE $8.50
  • P/E Ratio
  • ELVN N/A
  • BHE $36.68
  • Revenue Growth
  • ELVN N/A
  • BHE N/A
  • 52 Week Low
  • ELVN $13.30
  • BHE $30.73
  • 52 Week High
  • ELVN $30.03
  • BHE $52.57
  • Technical
  • Relative Strength Index (RSI)
  • ELVN 49.43
  • BHE 46.40
  • Support Level
  • ELVN $19.30
  • BHE $38.48
  • Resistance Level
  • ELVN $20.28
  • BHE $39.87
  • Average True Range (ATR)
  • ELVN 1.19
  • BHE 1.10
  • MACD
  • ELVN 0.15
  • BHE -0.08
  • Stochastic Oscillator
  • ELVN 59.11
  • BHE 26.53

About ELVN Enliven Therapeutics Inc.

Enliven Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics. Its product candidates include ELVN-001 is designed to specifically target the BCR-ABL fusion gene product, the oncogenic driver for patients with chronic myeloid leukemia (CML), ELVN-002 is designed to inhibit wild-type HER2 and key mutations of HER2.

About BHE Benchmark Electronics Inc.

Benchmark Electronics Inc is engaged in product designing, engineering services, technology solutions, and manufacturing services (electronic manufacturing services (EMS) and precision technology services). It serves various industries, including aerospace & defense (A&D), medical technologies, complex industrials, semiconductor capital equipment, next-generation telecommunications, and high-end computing. Its geographical segments are the Americas, Asia and Europe of which key revenue is derived from the Americas.

Share on Social Networks: